Zulvac 1+8 Bovis

RSS

Authorised

This medicine is authorised for use in the European Union

inactivated bluetongue virus, serotypes 1 and 8
MedicineVeterinaryAuthorised

Icelandic is available via eTranslation, the European Commission's machine translation service.

Translate to Icelandic | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

Up-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website

български (BG) (93.36 KB - PDF)

Skoða

español (ES) (81.97 KB - PDF)

Skoða

čeština (CS) (93.99 KB - PDF)

Skoða

dansk (DA) (83.34 KB - PDF)

Skoða

Deutsch (DE) (82.76 KB - PDF)

Skoða

eesti (ET) (82.18 KB - PDF)

Skoða

ελληνικά (EL) (93.76 KB - PDF)

Skoða

français (FR) (82.44 KB - PDF)

Skoða

Gaeilge (GA) (83.57 KB - PDF)

Skoða

hrvatski (HR) (92.27 KB - PDF)

Skoða

italiano (IT) (82.29 KB - PDF)

Skoða

latviešu (LV) (94.29 KB - PDF)

Skoða

lietuvių (LT) (94.03 KB - PDF)

Skoða

magyar (HU) (94.15 KB - PDF)

Skoða

Malti (MT) (95.95 KB - PDF)

Skoða

Nederlands (NL) (82.05 KB - PDF)

Skoða

polski (PL) (95.62 KB - PDF)

Skoða

português (PT) (83.01 KB - PDF)

Skoða

română (RO) (94.17 KB - PDF)

Skoða

slovenčina (SK) (94.08 KB - PDF)

Skoða

slovenščina (SL) (82.27 KB - PDF)

Skoða

suomi (FI) (81.54 KB - PDF)

Skoða

svenska (SV) (82.05 KB - PDF)

Skoða

Íslenska (IS) (83.29 KB - PDF)

Skoða

norsk (NO) (82 KB - PDF)

Skoða

Product information

български (BG) (91.78 KB - PDF)

Skoða

español (ES) (81.51 KB - PDF)

Skoða

čeština (CS) (92.48 KB - PDF)

Skoða

dansk (DA) (82.05 KB - PDF)

Skoða

Deutsch (DE) (81.72 KB - PDF)

Skoða

eesti (ET) (81.22 KB - PDF)

Skoða

ελληνικά (EL) (91.79 KB - PDF)

Skoða

français (FR) (81.63 KB - PDF)

Skoða

Gaeilge (GA) (81.36 KB - PDF)

Skoða

hrvatski (HR) (91.56 KB - PDF)

Skoða

italiano (IT) (81.76 KB - PDF)

Skoða

latviešu (LV) (92.14 KB - PDF)

Skoða

lietuvių (LT) (92.19 KB - PDF)

Skoða

magyar (HU) (92.76 KB - PDF)

Skoða

Malti (MT) (93.86 KB - PDF)

Skoða

Nederlands (NL) (81.15 KB - PDF)

Skoða

polski (PL) (93.22 KB - PDF)

Skoða

português (PT) (82.53 KB - PDF)

Skoða

română (RO) (91.73 KB - PDF)

Skoða

slovenčina (SK) (81.75 KB - PDF)

Skoða

slovenščina (SL) (81.76 KB - PDF)

Skoða

suomi (FI) (81.11 KB - PDF)

Skoða

svenska (SV) (81.47 KB - PDF)

Skoða

Íslenska (IS) (81.52 KB - PDF)

Skoða

norsk (NO) (81.52 KB - PDF)

Skoða

български (BG) (93.36 KB - PDF)

Skoða

español (ES) (81.97 KB - PDF)

Skoða

čeština (CS) (93.99 KB - PDF)

Skoða

dansk (DA) (83.34 KB - PDF)

Skoða

Deutsch (DE) (82.76 KB - PDF)

Skoða

eesti (ET) (82.18 KB - PDF)

Skoða

ελληνικά (EL) (93.76 KB - PDF)

Skoða

français (FR) (82.44 KB - PDF)

Skoða

Gaeilge (GA) (83.57 KB - PDF)

Skoða

hrvatski (HR) (92.27 KB - PDF)

Skoða

italiano (IT) (82.29 KB - PDF)

Skoða

latviešu (LV) (94.29 KB - PDF)

Skoða

lietuvių (LT) (94.03 KB - PDF)

Skoða

magyar (HU) (94.15 KB - PDF)

Skoða

Malti (MT) (95.95 KB - PDF)

Skoða

Nederlands (NL) (82.05 KB - PDF)

Skoða

polski (PL) (95.62 KB - PDF)

Skoða

português (PT) (83.01 KB - PDF)

Skoða

română (RO) (94.17 KB - PDF)

Skoða

slovenčina (SK) (94.08 KB - PDF)

Skoða

slovenščina (SL) (82.27 KB - PDF)

Skoða

suomi (FI) (81.54 KB - PDF)

Skoða

svenska (SV) (82.05 KB - PDF)

Skoða

Íslenska (IS) (83.29 KB - PDF)

Skoða

norsk (NO) (82 KB - PDF)

Skoða

Product details

Name of medicine
Zulvac 1+8 Bovis
Active substance
  • inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP
  • inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02
International non-proprietary name (INN) or common name
inactivated bluetongue virus, serotypes 1 and 8

Pharmacotherapeutic group

  • Immunologicals
  • Immunologicals for Bovidae
  • Cattle
  • Inactivated viral vaccines
  • bluetongue virus

Authorisation details

EMA product number
EMEA/V/C/002473

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.

Assessment history

This page was last updated on

Share this page